Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1Burkitt Lymphoma 1

Interventions

Rituximab 30Cyclophosphamide 25Filgrastim 19Methotrexate 15fludarabine phosphate 13Etoposide 13Cytarabine 13Peripheral Blood Stem Cell Transplantation 12Cyclosporine 11Vincristine 10Mycophenolic Acid 10Whole-Body Irradiation 9Antilymphocyte Serum 9Radiotherapy 8Granulocyte Colony-Stimulating Factor 8CT-P10 8fludarabine 7Prednisone 7Doxorubicin 7Dexamethasone 7merphos 6Tacrolimus 6Melphalan 6Calcium Dobesilate 6dexamethasone acetate 5dexamethasone 21-phosphate 5deltacortene 5auricularum 5Methylprednisolone 5Leucovorin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Burkitt Lymphoma × pegylated granulocyte colony-stimulating factor, human × Clear all
NCT02392039 2019-04-23

Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Terminated
1 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡